Table 3.
Baseline characteristics in the treatment and control groups
| Allopurinol group | Control group | p value | |
|---|---|---|---|
| Patients, n | 21 | 19 | |
| Female:male | 8:13 | 10:9 | 0.4 |
| Age, years | 39.7 ± 10.0 | 40.1 ± 10.8 | 0.9 |
| Blood pressure | |||
| Hypertension, n | 9 | 9 | |
| SBP, mm Hg | 139.1 ± 23.8 | 140.8 ± 17.1 | 0.8 |
| DBP, mm Hg | 88.1 ± 14.3 | 87.3 ± 11.0 | 0.8 |
| Upro/creat, mg/g | 959.9 ± 1046.3 | 835.9 ± 599.7 | 0.7 |
| Scr, mg/dl | 1.3 ± 0.5 | 1.4 ± 0.5 | 0.6 |
| eGFR, ml/min | 69.5 ± 26.5 | 63.6 ± 27.5 | 0.6 |
| UA, mg/dl | 7.9 ± 1.1 | 7.8 ± 1.1 | 0.7 |
| TG, mmol/l | 1.7 ± 1.4 | 1.6 ± 0.9 | 0.9 |
| TC, mmol/l | 4.8 ± 0.9 | 5.3 ± 1.3 | 0.2 |
| HDL, mmol/l | 1.2 ± 0.3 | 1.3 ± 0.4 | 0.1 |
| LDL, mmol/l | 3.1 ± 1.0 | 3.2 ± 1.1 | 0.9 |